Clinical trial Recruiting at 1 site Interventional Ages 12 and up

Comparing early and late pulmonary valve replacement in children with Tetralogy of Fallot

Official title: Early Versus Later Re-valving in Tetralogy of Fallot With Free Pulmonary Regurgitation - Combined Cross-sectional and Prospective, Multi-centre, Randomized, Parallel-group Clinical Trial

Run by Copenhagen University Hospital, Rigshospitalet · NCT04084132 · Data updated 2026-11-12

This study is testing whether replacing the pulmonary valve earlier or later in children with Tetralogy of Fallot can lead to better heart health and fewer problems down the road.

More Tetralogy of Fallot trials

Quick facts

Study typeInterventional
Ages12 Years and up
SexAll
Enrollment120 (estimated)
SponsorCopenhagen University Hospital, Rigshospitalet
Academic / other
Locations3 sites (Aarhus and 2 other locations)
StatusRecruiting
StartedApril 1, 2019
Main results expectedDecember 31, 2024
Study endsDecember 31, 2031
Registry record updatedSeptember 10, 2019
Trial IDNCT04084132 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are children with Tetralogy of Fallot who have undergone repair with a transannular patch and are suitable for adult-sized conduit implantation.

Probably not a fit

Patients with significant associated anomalies or those who are symptomatic may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the timing of pulmonary valve replacement in children diagnosed with Tetralogy of Fallot who experience free pulmonary regurgitation. The study aims to determine whether early intervention leads to better outcomes compared to later re-valving, as current guidelines are based on retrospective data. Participants will undergo MRI assessments to evaluate their right ventricular anatomy and function, which will guide the timing of the valve replacement procedure. The trial seeks to improve long-term heart function and reduce complications associated with pulmonary regurgitation.

Why it matters

Potential benefit: If successful, this study could lead to improved heart function and reduced complications for patients with Tetralogy of Fallot.

How similar studies have gone: While this approach is based on existing guidelines, it aims to provide new insights that could challenge current practices, indicating a novel exploration in this area.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. ToF with pulmonary stenosis repaired with a TAP within the first two years of life.
2. RVOT anatomy is suitable for implantation of an adult sized conduit ( 18 mm homograft or Contegra graft) as assessed by MRI.

Exclusion Criteria:

1. ToF with pulmonary atresia, ToF with common atrioventricular canal, ToF with absent pulmonary valve syndrome, major aortopulmonary collateral arteries and other significant associated anomalies.
2. Palliation with a shunt (Blalock-Taussig or central) at any time.
3. The patient is symptomatic.
4. Sustained supraventricular or ventricular arrhythmia.
5. RVEDVi \> 140 mL/m2 as assessed by MRI (appendix 1).
6. RVESVi \> 60 mL/m2 as assessed by MRI.
7. RVEF \< 50 % as assessed by MRI.
8. Moderate or severe tricuspid regurgitation as assessed by echocardiography or MRI.
9. Significant residual lesions requiring intervention (e.g. ventricular septal defect, aortic regurgitation, branch pulmonary artery stenosis).
10. Co-morbidity preventing exercise testing (e.g. genetics, neuro-cognitive dysfunction, physical disability).
11. Contraindication for MRI (e.g. permanent pacemaker, intra-cardiac defibrillator, intracranial ferro-magnetic device).
12. Pregnancy at time of inclusion.
13. Age \< 12 or unable to comply with instructions given during MRI or exercise testing.

Where it's running

  • Rigshospitalet
    Copenhagen, Denmark
    Recruiting
  • Aarhus University Hospital
    Aarhus, Denmark
    Not yet recruiting
  • Odense University Hospital
    Odense, Denmark
    Not yet recruiting

Study contacts

  • Principal investigator: Lars Søndergaard, MD, DMSc — Copenhagen University Hospital, Rigshospitalet
  • Study coordinator: Mathis Gröning, MD, DMSc
  • Email: mathis.groening@regionh.dk
  • Phone: +45 42404489

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.